Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Jan-02-22 | Jan-03-21 | Dec-29-19 | Dec-30-18 | Dec-31-17 | Jan-01-17 | Jan-03-16 | Dec-28-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| United States | 27,954.0 | 25,735.0 | 23,874.0 | 700.0 | 1,109.0 | | 18,333.0 | 17,432.0 |
| International | | | | | | | 13,097.0 | 14,881.0 |
| Other | 24,126.0 | 19,837.0 | 18,324.0 | 40,034.0 | 35,147.0 | | | |
| Pharmaceutical revenues | 52,080.0 | 45,572.0 | 42,198.0 | 40,734.0 | 36,256.0 | | 31,430.0 | 32,313.0 |
| Revenue growth [+] | 14.3% | 8.0% | 3.6% | 12.4% | | | -2.7% | 14.9% |
| United States | 8.6% | 7.8% | 3310.6% | -36.9% | | | 5.2% | 25.0% |
| International | | | | | | | -12.0% | 5.0% |
| EBITDA | 22,310.0 | 19,568.0 | 12,826.0 | 16,370.0 | 13,499.0 | 13,713.0 | 12,663.0 | 12,749.0 |
| EBITDA margin | 42.8% | 42.9% | 30.4% | 40.2% | 37.2% | | 40.3% | 39.5% |
| Depreciation and amortization | 4,029.0 | 4,006.0 | 3,910.0 | 3,802.0 | 2,416.0 | 886.0 | 929.0 | 1,053.0 |
| EBIT | 18,281.0 | 15,562.0 | 8,916.0 | 12,568.0 | 11,083.0 | 12,827.0 | 11,734.0 | 11,696.0 |
| EBIT margin | 35.1% | 34.1% | 21.1% | 30.9% | 30.6% | | 37.3% | 36.2% |
| Non-recurring charges | 100.0 | 100.0 | 100.0 | | | | | |
| Pre-tax income | | | | 12,568.0 | 11,083.0 | 12,827.0 | 11,734.0 | 11,696.0 |
| Pre-tax margin | | | | 30.9% | 30.6% | | 37.3% | 36.2% |
| |
| Capital expenditures | 1,198.0 | 863.0 | 950.0 | 1,012.0 | 936.0 | 927.0 | 1,063.0 | 977.0 |
| |
| Total assets | 64,376.0 | 66,158.0 | 56,292.0 | 56,636.0 | 59,450.0 | 27,477.0 | 26,144.0 | 25,803.0 |
| ROA | 25.9% | 20.8% | 13.7% | 18.9% | 1.4% | 39.0% | 36.0% | 36.0% |
| |
| Revenue Mix | 55.5% | 55.2% | 51.4% | 49.9% | 47.4% | | 44.9% | 43.5% |
| EBIT Mix | 77.7% | 79.3% | 44.5% | 63.5% | 61.0% | 63.0% | 66.8% | 55.8% |
|